Advertisement

ADVERTISEMENT

outcomes research

News
Predicting Clinical Outcomes of Patients With High-Risk MCL
06/18/2020
Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...
Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...
...
06/18/2020
Journal of Clinical Pathways
News
Assessing Frequency of Secondary Malignancies in Survivors of Hodgkin Lymphoma
06/17/2020
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study...
06/17/2020
Journal of Clinical Pathways
News
Long-Term Follow-Up of BTK Inhibitor in Symptomatic Treatment-Naïve CLL
06/15/2020
Long-term data from ACE-CL-001 further supports the favorable results of acalabrutinib in phase III studies for patients with symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL). Results of the study...
Long-term data from ACE-CL-001 further supports the favorable results of acalabrutinib in phase III studies for patients with symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL). Results of the study...
...
06/15/2020
Journal of Clinical Pathways
News
BTK Inhibitor Effective in Patients With Progressive, High-Risk CLL
06/15/2020
Bruton tyrosine kinase (BTK) inhibitor therapy is effective in patients with chronic lymphocytic leukemia (CLL) who are resistant to prior venetoclax treatment, according to a new study presented at the European...
Bruton tyrosine kinase (BTK) inhibitor therapy is effective in patients with chronic lymphocytic leukemia (CLL) who are resistant to prior venetoclax treatment, according to a new study presented at the European...
Bruton...
06/15/2020
Journal of Clinical Pathways
News
Reduced-Intensity Conditioning Regimens for Patients With NHL Undergoing Transplant
06/09/2020
Use of a more intense reduced-intensity conditioning and non-myeloablative conditioning (RIC-NMAC) regimen for allogeneic hematopoietic cell transplant (HCT) in patients with non-Hodgkin lymphoma should be considered...
Use of a more intense reduced-intensity conditioning and non-myeloablative conditioning (RIC-NMAC) regimen for allogeneic hematopoietic cell transplant (HCT) in patients with non-Hodgkin lymphoma should be considered...
Use of...
06/09/2020
Journal of Clinical Pathways
News
Final Results of KEYNOTE-100 for Patients With Advanced Ovarian Cancer
06/03/2020
Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of...
Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of...
...
06/03/2020
Journal of Clinical Pathways
News
Effective, Less Toxic Treatment Option Identified for Aggressive B-Cell Lymphoma
05/29/2020
Risk-adapted dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) therapy is effective and well tolerated in adults with Burkitt lymphoma regardless of age or...
Risk-adapted dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) therapy is effective and well tolerated in adults with Burkitt lymphoma regardless of age or...
...
05/29/2020
Journal of Clinical Pathways
News
Practice Patterns, Predictors of Survival for Older Patients With MCL
05/27/2020
A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...
A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...
A new...
05/27/2020
Journal of Clinical Pathways
News
Long-Term Outcomes of High-Dose CAR-T Therapy for Relapsed, Refractory CLL
05/12/2020
Chimeric antigen receptor T-cell targeting CD-19 (CAR T-19) may be more effective at a higher dose (5 x 108) than a standard lower dose (5 x 107) in patients with relapsed or refractory chronic lymphocytic leukemia...
Chimeric antigen receptor T-cell targeting CD-19 (CAR T-19) may be more effective at a higher dose (5 x 108) than a standard lower dose (5 x 107) in patients with relapsed or refractory chronic lymphocytic leukemia...
...
05/12/2020
Journal of Clinical Pathways
Research in Review
Patients With MCL and a Specific Mutation in Need of Alternative Frontline Therapies
08/21/2017
JCP Editors
Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August...
Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August...
...
08/21/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Psych Congress Regionals
July 18 ⁠–⁠ July 19
Advances in Inflammatory Bowel Disease Regionals
July 19 ⁠–⁠ July 20
July 24 ⁠–⁠ July 26
APP Institute Inflammatory Bowel Disease
July 26 ⁠–⁠ July 27
July 27 ⁠–⁠ July 28
July 27 ⁠–⁠ July 28
Psych Congress Regionals
August 8 ⁠–⁠ August 9
August 14 ⁠–⁠ August 17
August 16 ⁠–⁠ August 18
APP Institute Dermatology
August 16 ⁠–⁠ August 17
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use